Actively Recruiting
Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy
Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2022-10-31
2500
Participants Needed
1
Research Sites
627 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dilated cardiomyopathy (DCM) is an increasingly recognized cause of morbidity and mortality with heterogenous etiologies (eg, genetic, environment) and clinical manifestations, characterized by left ventricular (LV) systolic dysfunction and LV or biventricular dilation. Previous publications reported the three-year treated mortality rates remain high at 12%-20% and a reported 5-year mortality rate up to 50%, with death resulting from ventricular arrhythmia leading to sudden cardiac death (SCD) or advanced heart failure (HF). With large fields of view and high spatial resolution, Cardiac magnetic resonance (CMR) is the reference standard for assessing cardiac mass, volume, and function. CMR also provides non noninvasive characterization of the myocardium benefiting to differential diagnosis and risk stratification.
CONDITIONS
Official Title
Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Reduced left ventricular ejection fraction (LVEF less than 50%)
- Left ventricular end-diastolic volume more than 2 standard deviations above normal for body surface area and age
You will not qualify if you...
- Any signs of ischemic heart disease, including coronary angiography results, heart attacks, or coronary artery procedures
- Presence of hypertrophic cardiomyopathy, moderate-to-severe valve disease, or infiltrative diseases such as amyloidosis, sarcoidosis, or Fabry disease
- Continuous arrhythmias
- Unable to lie flat for imaging
- Pregnancy
- Contraindications to cardiac magnetic resonance imaging like severe claustrophobia, pacemakers, defibrillators, certain aneurysm clips, intraocular metal, or advanced kidney disease
- Diabetes with end organ damage
- Unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fuwai Hospital
Beijing, Beijing Municipality, China, 100037
Actively Recruiting
Research Team
M
Minjie Lu, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here